The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials
Joint Authors
Zeng, Xian-Tao
Yu, Hongsong
Xiao, Zheng
Wang, Chengqiong
Li, Nana
Chen, Ling
Feng, Jihong
Zhou, Ming-hua
Sun, Yong-ping
Wang, Yu-zhi
Liu, Shi-yu
Li, Cheng-wen
Yao, Xin-sheng
Source
Journal of Immunology Research
Issue
Vol. 2018, Issue 2018 (31 Dec. 2018), pp.1-18, 18 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2018-12-13
Country of Publication
Egypt
No. of Pages
18
Main Subjects
Abstract EN
Objective.
DC-CIK therapy included DC-CIK cells and Ag-DC-CIK cells.
To further confirm whether DC-CIK reconstructs the antitumor immunity and improves the tumor responses and reveals its optimal usage and combination with chemotherapy, we systematically reevaluated all the related studies.
Materials and Methods.
All studies about DC-CIK plus chemotherapy for NSCLC were collected from the published and ongoing database as CBM, CNKI, VIP, Wanfang, ISI, Embase, MEDLINE, CENTRAL, WHO-ICTRP, Chi-CTR, and US clinical trials (established on June 2017).
We evaluated their methodological bias risk according to the Cochrane evaluation handbook of RCTs (5.1.0), extracted data following the predesigned data extraction form, and synthesized the data using meta-analysis.
Results.
We included 28 RCTs (phase IV) with 2242 patients, but most trials had unclear bias risk.
The SMD and 95% CI of meta-analysis for CD3+ T cells, CD3+ CD4+ T cells, CD3+ CD8+ T cells, CD4+/CD8+ T cell ratio, CIK cells, NK cells, and Treg cells were as follows: 1.85 (1.39 to 2.31), 0.87 (0.65 to 1.10), 1.04 (0.58 to 1.50), 0.75 (0.27 to 1.22), 3.87 (2.48 to 5.25), 1.51 (0.99 to 2.03), and −2.31(−3.84 to −0.79).
The RR and 95% CI of meta-analysis for ORR and DCR were as follows: 1.38 (1.24 to 1.54) and 1.27 (1.20 to 1.34).
All differences were statistically significant between DC-CIK plus chemotherapy and chemotherapy alone.
Subgroup analysis showed that only DC-CIK cells could increase the CD3+T cells, CD3+ CD4+T cells, CD3+ CD8+T cells, and CD4+/CD8+ T cell ratio.
In treatment with one cycle or two cycles and combination with NP or GP, DC-CIK could increase the CD4+/CD8+ T cell ratio.
All results had good stability.
Conclusions.
DC-CIK therapy can simultaneously improve the antitumor immunity and tumor responses.
DC-CIK therapy, especially DC-CIK cells, can improve antitumor immunity through increasing the T lymphocyte subsets, CIK cell, and NK cells in peripheral blood.
The one cycle to two cycles may be optimal cycle, and the NP or GP may be optimal combination.
American Psychological Association (APA)
Xiao, Zheng& Wang, Chengqiong& Zhou, Ming-hua& Li, Nana& Sun, Yong-ping& Wang, Yu-zhi…[et al.]. 2018. The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials. Journal of Immunology Research،Vol. 2018, no. 2018, pp.1-18.
https://search.emarefa.net/detail/BIM-1193251
Modern Language Association (MLA)
Xiao, Zheng…[et al.]. The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials. Journal of Immunology Research No. 2018 (2018), pp.1-18.
https://search.emarefa.net/detail/BIM-1193251
American Medical Association (AMA)
Xiao, Zheng& Wang, Chengqiong& Zhou, Ming-hua& Li, Nana& Sun, Yong-ping& Wang, Yu-zhi…[et al.]. The Antitumor Immunity and Tumor Responses of Chemotherapy with or without DC-CIK for Non-Small-Cell Lung Cancer in China: A Meta-Analysis of 28 Randomized Controlled Trials. Journal of Immunology Research. 2018. Vol. 2018, no. 2018, pp.1-18.
https://search.emarefa.net/detail/BIM-1193251
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1193251